Anika Therapeutics, Inc.
ANIKNasdaqHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $112.8M | $119.9M | $120.8M | $113.8M | $147.8M | $130.5M |
| Operating income | −$11.1M | −$5.1M | $844,000 | $3.7M | $2.6M | −$28.3M |
| Net income | −$10.9M | −$56.4M | −$82.7M | −$14.9M | $4.1M | −$24.0M |
| Total assets | $190.3M | $202.7M | $270.6M | $349.1M | $347.5M | $365.6M |
| Total liabilities | — | — | — | — | — | — |
| Equity | $143.5M | $154.0M | $212.3M | $285.6M | $287.1M | $272.4M |
| EPS (diluted) | $-0.76 | $-3.83 | $-5.64 | $-1.02 | $0.28 | $-1.69 |
| Shares out. | 14.2M | 14.8M | 14.6M | 14.5M | 14.3M | 14.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −9.8%
- Net margin
- −9.6%
- Return on equity
- −7.6%
- Return on assets
- −5.7%
- Return on capital (ROCE)
- −6.6%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $10.12
- Revenue growth (YoY)
- −5.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −11.6%clean
- Piotroski F-Score
- 5/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 warning● 2 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Capital Management LlcPassive (13G)Apr 29, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Caligan Partners LpActivist (13D)Jan 27, 2026
- Trigran Investments, Inc.Passive (13G)Jan 8, 2026
- Blackrock Portfolio Management LlcPassive (13G)Oct 17, 2025
- Blackrock, Inc.Passive (13G)Apr 17, 2025
- Dimensional Fund Advisors LpPassive (13G)Jan 23, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Henneman John B IiiDirector | May 1, 2026 | Buy | 5,000 | $14.66 |
| Griffin Stephen D.Officer — President and CEO | Apr 30, 2026 | Buy | 12,200 | $12.29 |
| Colleran DavidOfficer — EVP, General Counsel, Corp Sec | Mar 14, 2026 | Option exercise | 9,388 | — |
| Griffin Stephen D.Officer — President and CEO | Mar 14, 2026 | Option exercise | 12,824 | — |
| Blanchard Cheryl RDirector | Mar 14, 2026 | Option exercise | 24,519 | — |
| Mcleod IanOfficer — SVP, CAO & Treasurer | Mar 14, 2026 | Option exercise | 3,774 | — |
| Colleran DavidOfficer — EVP, General Counsel, Corp Sec | Mar 9, 2026 | Option exercise | 5,465 | — |
| Blanchard Cheryl RDirector | Mar 9, 2026 | Option exercise | 20,001 | — |
| Mcleod IanOfficer — SVP, CAO & Treasurer | Mar 9, 2026 | Option exercise | 2,197 | — |
| Vogt Susan L NDirector | Jun 20, 2025 | Grant | 14,164 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 565,572 | 5.4 | +2.4% |
| Apr 30, 2026 | 552,247 | 4.3 | -14.3% |
| Apr 15, 2026 | 644,571 | 4.9 | -6.4% |
| Mar 31, 2026 | 688,325 | 5.5 | -3.4% |
| Mar 13, 2026 | 712,348 | 4.8 | -2.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Director / officer changeApr 29, 2026
- Results of operations · Director / officer changeFeb 26, 2026
- Results of operations · Director / officer changeJan 8, 2026
- Results of operations · Other material eventNov 5, 2025
- Results of operationsJul 30, 2025
- Regulation FD disclosureJul 30, 2025
- Director / officer change · Shareholder voteJun 24, 2025
- Results of operationsMay 9, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- DEFA14AJun 1, 2026
- 4May 4, 2026
- 4Apr 30, 2026
- 10-QFORM 10-QApr 30, 2026
- SCHEDULE 13GApr 29, 2026
- 8-KFORM 8-KApr 29, 2026
- ARSApr 28, 2026
- DEFA14AApr 28, 2026
- DEF 14AApr 28, 2026
- SCHEDULE 13G/AMar 26, 2026
- 4Mar 23, 2026
- 4Mar 17, 2026
- 4Mar 17, 2026
- 4Mar 17, 2026
- 4Mar 17, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.